REAL-TIME CANCER THERAPY MONITORING – Cadex Genomics | Bill Haack & Greg Schafer

Bill Haack, CEO and Greg Schafer, CCO are part of a seasoned team
that is leading an initiative to transform the way in which
responsiveness to cancer treatment is assessed. If all goes to
plan, the technology being developed at Cadex Genomics could
impact the course of treatment for millions of late-stage (solid
state) cancer patients worldwide.


At the heart of the matter is a blood-based assay called Alibrex
which uses a low-cost PCR protocol to examine cell-free DNA. By
comparing two blood draws taken ~2 weeks apart in patients being
treated for cancer, the test is used to determine whether a tumor
is responding to that treatment. The key is in its 24-hour
turn-around time to assess responsiveness, which allows quicker
adjustments in treatment than currently possible and may help to
prevent side effects associated with unnecessary or ineffective
therapies.


Though still in clinical development at sites in the US, Canada
and Israel, early results have shown the test to be highly
specific, meaning that it correctly identifies non-responsive
(disease-progressing) patients 100% of the time, thereby flagging
patients who require a different course of treatment.


With a new funding round well underway they plan to complete
algorithm validation by 2020/early 2021 and to begin
commercialization in mid-2021. We wish them all the best as they
roll out this important development in oncology molecular
diagnostics.


Find out more about Cadex Genomics:
w: https://www.cadexgenomics.com/en/home
LI: https://www.linkedin.com/company/cadexgenomics/
Twitter: https://twitter.com/cadexgenomics?lang=en
FB: https://www.facebook.com/cadexgenomics/
E: bhaack@cadexgenomics.com, investors@cadexgenomics.com